NEW YORK (GenomeWeb News) – Barcelona-based plasma products manufacturer Grifols has acquired a 60 percent stake in Progenika Biopharma for €37 million ($48.4 million), the firms announced earlier this week.

Grifols paid 50 percent of the consideration in cash, with the other 50 percent coming in the form of non-voting (Class B) Grifols shares.

Vizcaya, Spain-based Progenika develops molecular diagnostics tests and DNA chips for disease diagnosis and prognosis. In particular, it has developed tests for evaluating transfusional compatibility studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.